Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance

Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on a histological continuum between 'low-grade' (Grade 1, 2 and 3A FL) and diffuse large B-cell lymphoma (DLBCL) appearing to share features with each. Clinical characteristics and outcomes are poorly understood due to...

Full description

Saved in:

Bibliographic Details
Published in:	Haematologica (Roma) Vol. 108; no. 9; pp. 2444 - 2453
Main Authors:	Barraclough, Allison, England, James T, Villa, Diego, Wight, Joel, Hapgood, Greg, Conn, Jason, Doo, Nicole Wong, Li, Eric Wenlong, Gilbertson, Michael, Shaw, Briony, Bishton, Mark J, Saeed, Malik, Ratnasingam, Sumita, Abeyakoon, Chathuri, Chong, Geoff, Wai, Shin Hnin, Ku, Matthew, Lee, Hui-Peng, Fleming, Kathryn, Tam, Constantine, Douglas, Genevieve, Cheah, Chan Y, Ng, Zi Yun, Rolfe, Tukten, Mills, Anthony K, Hamad, Nada, Cashman, Helen, Gleeson, Mary, Narayana, Manjunath, Hawkes, Eliza A
Format:	Journal Article
Language:	English
Published:	Italy Fondazione Ferrata Storti 01-09-2023 Ferrata Storti Foundation
Subjects:	Non-Hodgkin Lymphoma
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on a histological continuum between 'low-grade' (Grade 1, 2 and 3A FL) and diffuse large B-cell lymphoma (DLBCL) appearing to share features with each. Clinical characteristics and outcomes are poorly understood due to lack of adequate representation in prospective trials and large-scale analyses. We analyzed 157 G3BFL cases from 18 international centers, and two comparator groups; G3AFL (n=302) and DLBCL (n=548). Composite histology with DLBCL or low-grade FL occurred in approximately half of G3BFL cases. With median 5 years follow-up, G3BFL overall (OS; P.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 HC, MG, MN, JTE, GH, JC, MG, BS, MS, SR, CA, SHW, KF, GD, ZN and TR have no conflicts of interest to disclose. AB has received speakers fees from Roche and sat on an advisory board for Gilead. DV has received honoraria from and sat on advisory boards for Roche, Kite/Gilead, BMS/Celgene, Bei-Gene, Janssen, Abbvie, AstraZeneca, and Kyowa Kirin; and had received research funding* from Roche and AstraZeneca; JW has received honoraria, travel support, and speakers fees from and sat on advisory boards for Abbvie; has received honoraria and travel support from Janssen; and sat on advisory boards for Alexion. MJB has received honoraria from Celltrion, Tevapharma, Gilead, and F. Hofmann-La Roche; has sat on advisory boards for F. Hofmann-La Roche; and has received travel expenses from BMS. GC has sat on advisory boards for BMS; and has received research funding from BMS, Hutch-Med, Pharmacyclics, Merck Serono, AstraZeneca, MorphoSys, Incyte, SeaGen, Isofol, Bayer, and Amgen. MK has sat on advisory boards for Roche and Antengene. H-PL has sat on advisory boards for Roche; and has received honoraria from BeiGene. CT has received honoraria and research funding from Abbvie, Janssen, and BeiGene. CYC has provided consulting services for, has sat on advisory boards for, and has received honoraria from Roche, Janssen, MSD, Gilead, Astra-Zeneca, Lilly, TG therapeutics, Beigene, Novartis, and BMS; and has received research funding from BMS, Roche, Abbvie, and MSD. AKM has received speaker’s fees from Abbvie; has sat on advisory boards for SOBI and Novartis; and had meeting sponsorship from Amgen and MSD. NH has sat on advisory boards for Roche, Gilead, Abbvie, Novartis, Janssen, and Jazz pharma. EAH has received research funding* from Bristol Myers Squibb/Celgene, Merck KgA, AstraZeneca, and Roche; has sat on advisory boards for Roche, Antigene, Bristol Myers Squibb, AstraZeneca, Novartis, Merck Sharpe Dohme, Gilead, and Beigene; has received speaker’s fees from Roche, AstraZeneca, Abbvie, Janssen, and Regeneron; and provided consultancy services to Specialised therapeutics. (Paid to institution). Disclosures The authors will willingly share the original data on request made by e-mail to the corresponding author. Contributions AB designed the research study, contributed and analyzed the data and wrote the paper. EAH designed and supervised the research study, analyzed the data and wrote the paper. JTE, JW, GH, JC, MG, BS, MJB, MS, SR, CA, GC, SHW, MK, H-PL, KF, CT, GD, CYC, ZN, TR, AKM, NH, HC, MG, MN and DV contributed data and wrote the paper. Data-sharing statement
ISSN:	0390-6078 1592-8721
DOI:	10.3324/haematol.2022.281375